Genetic and molecular factors in drug-induced liver injury: A review

Current Drug Safety

Volumn 2, Issue 2, 2007, Pages 97-112

  Pachkoria, Ketevan ^a,c   Lucena, Ma Isabel ^a   Molokhia, Mariam ^a   Cueto, Raquel ^a   Serrano Carbalo, Alfonso ^a   Carvajal, Alfonso ^b   Andrade, Raúl J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

^c Facultad de Medicina   (Spain)

Author keywords

Drug induced liver injury (DILI); Genetic polymorphism; Genetic testing; II and III enzymes; Molecular mechanism of DILI; Phase I

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANALGESIC AGENT; ANTIINFECTIVE AGENT; CHLORPROMAZINE; CORTICOSTEROID; DIAZEPAM; DICLOFENAC; FLUCLOXACILLIN; FLUINDOSTATIN; HALOTHANE; IBUPROFEN; INDOMETACIN; LEFLUNOMIDE; LOSARTAN; MEPHENYTOIN; MIANSERIN; NAPROXEN; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PERHEXILINE; PHENYTOIN; SENNA EXTRACT; SULFONAMIDE; TETRABAMATE; TRAZODONE; TROGLITAZONE; UNINDEXED DRUG; WARFARIN;

ALCOHOL LIVER DISEASE; BILE DUCT DISEASE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG OVERDOSE; DRUG OXIDATION; DRUG TRANSFORMATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME ANALYSIS; HEREDITY; HETEROZYGOTE; HUMAN; INCIDENCE; LIPIDOSIS; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TOXIC HEPATITIS;

ANIMALS; DRUG THERAPY; ENZYMES; HEPATITIS, TOXIC; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 34249276062     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488607780598287     Document Type: Review

References (203)

1. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 916-7.
2. Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003; 23: 217-26.
3. Temple R. Policy developments in regulatory approval. Stat Med 2002; 21: 2939-48.
4. Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev 2004; 36: 301-12.
5. Ibanez L, Perez E, Vidal X, Laporte JR. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002; 37: 592-600.
6. Andrade RJ, Lucena MI, Fernandez MC, et al. Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.
7. Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32: 77-88.
8. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 2005; 45: 177-202.
9. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36: 451-5.
10. Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61: 135-43.
11. Maddrey WC. Drug-induced hepatotoxicity. J Clin Gastroenterol 2005; 39: 83-89.
12. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22: 145-55.
13. Egger T, Dormann H, Ahne G, et al. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions - a pilot study. Drugs Aging 2005; 22: 265-72.
14. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005; 44: 1209-25.
15. Larrey D. Hepatotoxicity of herbal remedies. J Hepatol 1997; 26(Suppl 1): 47-51.
16. Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. J Hepatol 1994; 21: 1075-9.
17. Seybold U, Landauer N, Hillebrand S, Goebel FD. Senna-induced hepatitis in a poor metabolizer. Ann Intern Med 2004; 141: 650-1.
18. Andrade RJ, Camargo R, Lucena MI, Gonzalez-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 2004; 3: 329-44.
19. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-38.
20. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52: 447-50.
21. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-8.
22. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16.
23. Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26(Suppl 2): 12-21.
24. Sevilla-Mantilla C, Ortega L, Agundez JA, Fernandez-Gutierrez B, Ladero JM, Diaz-Rubio M. Leflunomide-induced acute hepatitis. Dig Liver Dis 2004; 36: 82-4.
25. Morin S, Loriot MA, Poirier JM, et al. Is diclofenac a valuable CYP2C9 probe in humans? Eur J Clin Pharmacol 2001; 56: 793-7.
26. Aithal GP, Day CP, Leathart JB, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10: 511-8.
27. Yasar U, Eliasson E, Forslund-Bergengren C, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001; 57: 729-35.
28. Bort R, Mace K, Boobis A, et al. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 1999; 58: 787-96.
29. Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39: 1430-40.
30. Kirchheiner J, Kudlicz D, Meisel C, et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003; 74: 186-94.
31. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743-52.
32. Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 25-31.
33. Baumann P. Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test. Encephale 1986; 12: 143-8.
34. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989; 45: 72-9.
35. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-9.
36. Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 2003; 56: 653-7.
37. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation pheno-type and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-3.
38. Brosen K, de Morais SM, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Pharmacogenetics 1995; 5: 312-7.
39. Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. J Hepatol 1994; 21: 1075-9.
40. Pachkoria K, Lucena MI, Ruiz-Cabello F, Crespo E, Cabello MR, Andrade RJ. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol 2007; 5: [Epub ahead of print]
41. Dorado P, Berecz R, Caceres MC, Gonzalez I, Cobaleda J, Llerena A. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. Clin Chem Lab Med 2005; 43: 275-9.
42. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7: 193-2.
43. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53: 111-2.
44. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with pethexiline liver injury. Gut 1984; 25: 1057-4.
45. Watson RG, Olomu A, Clements D, Waring RH, Mitchell S, Elias E. A proposed mechanism for chlorpromazine jaundice - defective hepatic sulphoxidation combined with rapid hydroxylation. J Hepatol 1988; 7: 72-8.
46. Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit 2004; 26: 127-1.
47. Caccia S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998; 34: 281-2.
48. Otani K, Kaneko S, Tasaki H, Fukushima Y. Hepatic injury caused by mianserin. BMJ 1989; 299: 9.
49. Yasui N, Otani K, Kaneko S, et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995; 17: 333-5.
50. Hull M, Jones R, Bendall M. Fatal hepatic necrosis associated with trazodone and neuroleptic drugs. BMJ 1994; 309: 378.
51. Inoue K, Inazawa J, Nakagawa H, et al. Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. Jpn J Hum Genet 1992; 37: 133-8.
52. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42. Review.
53. Hsieh KP, Lin YY, Cheng CL, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2001; 29: 268-3.
54. Klees TM, Sheffels P, Thummel KE, Kharasch ED. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology 2005; 102: 550-6.
55. Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 2001; 98: 3369-4.
56. Gnerre C, Blattler S, Kaufmann MR, Looser R, Meyer UA. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 2004; 14: 635-5.
57. Kostrubsky VE, Szakacs JG, Jeffery EH, et al. Role of CYP3A in ethanol-mediated increases in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol 1997; 143: 315-3.
58. Lakehal F, Dansette PM, Becquemont L, et al. Indirect cytotoxicity, of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol 2001; 14: 694-1.
59. Andrade RJ, Salmeron FJ, Lucena MI. Drug Hepatotoxicity. En: The Clinician's Guide to Liver Disease, Reddy KR & Faust T eds. Slack Incorporated, NJ, USA. 2005.
60. Kassahun K, Pearson PG, Tang W, et al. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 200; 14: 62-0.
61. Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother 2006; 40: 753-7.
62. Lucena MI, Andrade RJ, Vicioso L, Gonzalez FJ, Pachkoria K, Garcia-Munoz B. Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. World J Gastroenterol 2006; 12: 5244-5246.
63. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2 D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003; 59: 303-2.
64. Rizzo G, Renga B, Mencarelli A, Pellicciari R, Fiorucci S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 289-3.
65. Chen B, Zhang WX, Cai WM. The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. Eur J Clin Pharmacol 2006; 62: 355-9.
66. Gross M, Kruisselbrink T, Anderson K, et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 1999; 8: 683-2.
67. Evans DA. N-acetyltransferase. Pharmacol Ther 1989; 42: 157-234.
68. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37: 25-79.
69. Agundez JA, Olivera M, Martinez C, Ladero JM, Benitez J. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996; 6: 423-8.
70. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994; 4: 125-4.
71. Xie HG, Xu ZH, Ou-Yang DS, et al. Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. Pharmacogenetics 1997; 7: 503-4.
72. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-9.
73. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 1976; 19: 610-5.
74. Lauterburg BH, Smith CV, Todd EL, Mitchell JR. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther 1985; 235: 566-70.
75. Mitchell JR, Thorgeirsson UP, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 1975; 18: 70-9.
76. Mitchell JR, Potter WZ. Drug metabolism in the production of liver injury. Med Clin North Am 1975; 59: 877-5.
77. Olomu AB, Vickers CR, Waring RH, et al. High incidence of poor sulfoxidation in patients with primary biliary cirrhosis. N Engl J Med 1988; 318: 1089-2.
78. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000; 356: 1587-91.
79. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4: 489-99.
80. Oude Elferink RP, Meijer DK, Kuipers F, Jansen PL, Groen AK, Groothuis GM. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim Biophys Acta 1995; 1241: 215-8.
81. Smith AJ, van Helvoort A, van Meer G, et al. MDR3 P-glycoprotein, a phosphatidyleholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 2000; 275: 23530-9.
82. Konig J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta, 1999; 1461: 377-94.
83. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.
84. Grant CE, Kurz EU, Cole SP, Deeley RG. Analysis of the intron-exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA. Genomics 1997; 45: 368-8.
85. Tsujii H, Konig J, Rost D, Stockel B, Leuschner U, Keppler D. Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterology 1999; 117: 653-60.
86. Mayer R, Kartenbeck J, Buchler M, Jedlitschky G, Leier I, Keppler D. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J Cell Biol 1995; 131: 137-50.
87. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999; 55: 929-37.
88. Awasthi CW, Awasthi S, Zimniak P. Multiple transport protein involved in the detoxification of endo- and xenobiotics. Front Biosci 1997; 15: 427-7.
89. Cantz T, Nies AT, Brom M, Hofmann AF, Keppler D. MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells. Am J Physiol Gastrointest Liver Physiol 2000; 278: G522-31.
90. Bolder U, Trang NV, Hagey LR, et al. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology 1999; 117: 962-71.
91. Iverson SL, Uetrecht JP. Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. Chem Res Toxicol 2001; 14: 175-81.
92. Dietrich CG, de Waart DR, Ottenhoff R, Bootsma AH, van Gennip AH, Elferink RP. Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo. Carcinogenesis 2001; 22: 805-11.
93. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217-27.
94. Dixon PH, Weerasekera N, Linton KJ, et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 2000; 9: 1209-17.
95. Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous, non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999; 353: 210-1.
96. de Vree JM, Jacquemin E, Sturm E, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A 1998; 95: 282-7.
97. Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001; 120: 1459-67.
98. Njoku DB, Greenberg RS, Bourdi M, et al. Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cobort of pediatric anesthesiologists. Anesth Analg 2002; 94: 243-9.
99. Aithal GP. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Expert Opin Drug Saf 2004; 3: 519-23.
100. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004; 38(Suppl 2): S44-8.
101. Hautekeete ML. Hepatotoxicity of antibiotics. Acta Gastroenterol Belg 1995; 58: 290-6.
102. Bourdi M, Masubuchi Y, Reilly TP, et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 2002; 35: 289-8.
103. Masubuchi Y, Bourdi M, Reilly TP, Graf ML, George JW, Pohl LR. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem Biophys Res Commun 2003; 304: 207-12.
104. Grypioti AD. Liver Oxidant Stress Induced By Paracetamol Overdose. Int J Pharmacol 2006; 4: 1531-76.
105. Lucena MI, Pachkoria K, Ruiz-Cabello F, et al. Lack of association of interleukin-10 promoter gene variants in drug-induced idiosyncratic liver injury (DILI) in a Spanish population. Basic and Clinical Pharmacology & Toxicology. 20th Congress of the Spanish Clinical Pharmacology Society Puerto de la Cruz (Tenerife), Spain. Pharmacol Toxicol 2006; 99: 29-50.
106. Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate - induced hepatitis. Gastroenterology 1999; 117: 1181-6.
107. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916-9.
108. Berson A, Freneaux E, Larrey D, et al. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol 1994; 20: 336-42.
109. Andrade RJ, Lucena MI, Alonso A, et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004; 39: 1603-12.
110. Lemasters JJ. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. Gastroenterology 2005; 129: 351-60.
111. Ding WX, Ni HM, DiFrancesca D, Stolz DB, Yin XM. Bid-dependent generation of oxygen radicals promotes death receptor activation-induced apoptosis in murine hepatocytes. Hepatology 2004; 40: 403-13.
112. Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem 2004; 73: 87-106.
113. Herman B, Nieminen AL, Gores GJ, Lemasters JJ. Irreversible injury in anoxic hepatocytes precipitated by an abrupt increase in plasma membrane permeability. FASEB J 1988; 2: 146-51.
114. Gores GJ, Herman B, Lemasters JJ. Plasma membrane bleb formation and rupture: a common feature of hepatocellular injury. Hepatology 1990; 11: 690-8.
115. Nishimura Y, Romer LH, Lemasters JJ. Mitochondrial dysfunction and cytoskeletal disruption during chemical hypoxia to cultured rat hepatic sinusoidal endothelial cells: the pH paradox and cytoprotection by glucose, acidotic pH, and glycine. Hepatology 1998; 27: 1039-49.
116. Kaplowitz N. Cell death at the millennium. Implications for liver diseases. Clin Liver Dis 2000; 4: 1-23.
117. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-30.
118. Hatano E, Bradham CA, Stark A, Iimuro Y, Lemasters JJ, Brenner DA. The mitochondrial permeability transition augments Fas-induced apoptosis in mouse hepatocytes. J Biol Chem 2000; 275: 11814-23.
119. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-90.
120. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35.
121. Uehara T, Bennett B, Sakata ST, et al. JNK mediates hepatic ischemia reperfusion injury. J Hepatol 2005; 42: 850-9.
122. Kaplowitz N. Liver biology and pathobiology. Hepatology 2006; 43: 235-238. Review.
123. Kottlors M, Jaksch M, Ketelsen UP, Weiner S, Glocker FX, Lucking CH. Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromuscul Disord 2001; 11: 757-9.
124. Krahenbuhl S, Brandner S, Kleinle S, Liechti S, Straumann D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 2000; 20: 346-8.
125. McLaughlin DB, Eadie MJ, Parker-Scott SL, et al. Valproate metabolism during valproate-associated hepatotoxicity in a surviving adult patient. Epilepsy Res 2000; 41: 259-68.
126. Pons C, Dansette PM, Gregeois J, Homberg JC, Billett EE, Mansuy D. Human anti-mitochondria autoantibodies appearing in iproniazid-induced immunoallergic hepatitis recognize human liver monoamine oxidase B. Biochem Biophys Res Commun 1996; 218: 118-24.
127. Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis 2000; 13: 5-11.
128. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, ed. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1977; 10.
129. Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11: 969-88.
130. Walgren JL, Michell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005; 35: 325-61. Review.
131. Lucena MI, Andrade RJ, Fernandez MC, et al. Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatias Asociadas a Medicamentos (GEHAM)). Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006; 44: 850-6.
132. Sun L, Luo C, Long J, Wei D, Liu J. Acrolein is a mitochondrial toxin: effects on respiratory function and enzyme activities in isolated rat liver mitochondria. Mitochondrion 2006; 6: 136-42.
133. Benowitz NL, Peng M, Jacob P 3rd. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharmacol Ther 2003; 74: 468-74.
134. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001; 24: 483-90.
135. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22: 169-83.
136. Favreau JT, Ryu ML, Braunstein G, et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 2002; 136: 590-5.
137. Nadir A, Agrawal S, King PD, Marshall JB. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am J Gastroenterol 1996; 91: 1436-8.
138. Stevens T, Qadri A, Zein NN. Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxy-cut. Ann Intern Med 2005; 142: 477-8.
139. Humberston CL, Akhtar J, Krenzelok EP. Acute hepatitis induced by kava kava. J Toxicol Clin Toxicol 2003; 41: 109-13.
140. Batchelor WB, Heathcote J, Wanless IR. Chaparral-induced hepatic injury. Am J Gastroenterol 1995; 90: 831-3.
141. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41: 1179-97.
142. Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001; 56: 1405-9.
143. Black M. Diagnostic methods in liver diseases. Med Clin North Am 1975; 59(4): 1015-23.
144. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005; 33: 1-5.
145. Lucena MI, Andrade RJ. Increasing the detection of hepatotoxic response in clinical practice: a quality commitment. Rev Esp Enferm, Dig 2005; 97: 145-53.
146. Johnson GC, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001; 29(2): 233-7.
147. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005; 37(11): 1217-23.
148. Davey SG, Ebrahim S, Lewis S, Hansell AL, Palmer LJ, Burton PR. Genetic epidemiology and public health: hope, hype, and future prospects. Lancet 2005; 366(9495): 1484-98.
149. Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005; 366(9493): 1315-23.
150. Clayton DG, Walker NM, Smyth DJ, et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat Genet 2005; 37(11): 1243-6.
151. Lash LH, Hines RN, Gonzalez FJ, Zacharewski TR, Rothstein MA. Genetics and susceptibility to toxic chemicals: do you (or should you) know your genetic profile? J Pharmacol Exp Ther 2003; 305(2): 403-9.
152. Welch KD, Reilly TP, Bourdi M, et al. Genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice. Chem Res Toxicol 2006; 19: 223-33.
153. Meyer UA, Gut J. Genomics and the prediction of xenobiotic toxicity. Toxicology 2002; 181: 463-6.
154. Nelson DR, Strobel HW. Evolution of Cytochrome P-450 Proteins Mol Biol 1987; 6: 572-93.
155. Nebert DW, Adesnik M, Coon MJ, et al. The P450 gene superfamily: Recommended nomenclature. DNA 1987; 6: 1-11.
156. Nebert DW, Vesell ES. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol 2004; 500: 267-80.
157. Nebert DW. "Extreme discordant phenotype" methodology: an intuitive approach to clinical pharmacogenetics. Eur J Pharmacol 2000; 410: 107-20.
158. Hoggart CJ, Parra EJ, Shriver MD, et al. Control of confounding of genetic associations in stratified populations. Am J Hum Genet 2003; 72: 1492-1504.
159. Campbell CD, Ogburn EL, Lunetta KL, et al. Demonstrating stratification in a European American population. Nat Genet. 2005; 37: 868-72.
160. Becquemont L. Clinical relevance of pharmacogenetics. Drug Metab Rev 2003; 35: 277-85.
161. Peire MA, Lucena MI, Ruiz-Extremera A, Jara P, Romero-Gonzalez J, Andrade RJ. Drug-induced hepatotoxicity in children. Where we are and where were are going. An Esp Pediatr 2002; 56: 434-42.
162. Squires RH Jr, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148: 652-58.
163. Molokhia M, McKeigue P. EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics 2006; 7: 633-8.
164. Zimmerman H. Drug-induced liver disease. In: Schiff E, Sorrell M, Maddrey W. Schiff's Diseases of Liver. 8th ed. Philadelphia, PA: Lippincott-Raven Publishers. 1999; 973-1064.
165. Farrell GC, Drug induced liver disease. London: Churchill-Livingstone 1994.
166. Pineiro-Carrero VM, Pineiro EO. Liver 10.1542/peds.113.4.S1. 1097. Pediatrics 2004; 113(4): 1097-1106.
167. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996; 156: 1327-32.
168. Larrey D. Hepatotoxicity: also, phytotherapy. Gastroenterol Clin Biol 1992; 16: 913-5.
169. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004; 10: 1018-23.
170. de Boer NK, Mulder CJ, van Bodegraven AA. Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth J Med 2005; 63: 444-6.
171. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. Hepatology 2001; 33: 1009-13.
172. Patel KP. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 2191-3.
173. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999; 15: 367-73.
174. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 2006; 5: 231-49.
175. Krahenbuhl S. Mitochondria: important target for drug toxicity? J Hepatol 2001; 34: 334-6.
176. Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol 2003; 41: 1226-32.
177. Jackson MR, Craft JA, Burchell B. Nucleotide and deduced amino acid sequence of human liver microsomal epoxide hydrolase. Nucleic Acids Res 1987; 15: 7188.
178. Hartsfield JK, Jr, Sutcliffe MJ, Everett ET, Hassett C, Omiecinski CJ, Saari JA. Assignment1 of microsomal epoxide hydrolase (EPHX1) to human chromosome 1q42.1 by in situ hybridization. Cytogenet Cell Genet 1998; 83: 44-45.
179. Ema M, Matsushita N, Sogawa K, et al. Human arylhydrocarbon receptor: functional expression and chromosomal assignment to 7p21. J Biochem (Tokyo) 1994; 116: 845-851.
180. Le Beau MM, Carver LA, Espinosa R, III, Schmidt JV, Bradfield CA. Chromosomal localization of the human AHR locus encoding the structural gene for the Ah receptor to 7p21→p15. Cytogenet Cell Genet 1994; 66: 172-6.
181. Walisser JA, Glover E, Pande K, Liss AL, Bradfield CA. Aryl hydrocarbon receptor-dependent liver development and hepatotoxicity are mediated by different cell types. Proc Natl Acad Sci U S A 2005; 102: 17858-63.
182. Blum M, Heim M, Meyer UA. Nucleotide sequence of rabbit NAT2 encoding polymorphic liver arylamine N-acetyltransferase (NAT). Nucleic Acids Res 1990; 18: 5295.
183. Hickman D, Risch A, Buckle V, et al. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994; 297 ( Pt 3): 441-5.
184. Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 1995; 28: 328-32.
185. Barclay ML, Sawyers SM, Begg EJ, et al. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 2003; 13: 627-32.
186. Gough AC, Smith CA, Howell SM, Wolf CR, Bryant SP, Spurr NK. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis. Genomics 1993; 15: 430-32.
187. Silberstein DL, Shows TB. Gene for glutathione S-transferase-1 (GST1) is on human chromosome 11. Somatic Cell Genet 1982; 8: 667-75.
188. Suzuki T, Board P. Glutathione-S-transferase gene mapped to chromosome 11 is GST3 not GST1. Somat Cell Mol Genet 1984; 10: 319-20.
189. Yoon SJ, LeBlanc-Straceski J, Ward D, Krauter K, Kucherlapati R. Organization of the human keratin type II gene cluster at 12q13. Genomics 1994; 24: 502-8.
190. Harding D, Jeremiah SJ, Povey S, Burchell B. Chromosomal mapping of a human phenol UDP-glucuronosyltransferase, GNT1. Ann Hum Genet 1990; 54 ( Pt 1): 17-21.
191. Blazka ME, Wilmer JL, Holladay SD, Wilson RE, Luster MI. Role of proinflammatory cytokines in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol 1995; 133: 43-52.
192. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-12690.
193. Kayama F, Yoshida T, Elwell MR, Luster MI. Role of tumor necrosis factor-alpha in cadmium-induced hepatotoxicity. Toxicol Appl Pharmacol 1995; 131: 224-234.
194. Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin kin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000; 46: 540-5.
195. Baes M, Gulick T, Choi HS, Martinoli MG, Simha D, Moore DD. A new orphan member of the nuclear hormone receptor super-family that interacts with a subset of retinoic acid response elements. Mol Cell Biol 1994; 14: 1544-52.
196. Danan G, Homberg JC, Bernuau J, Roche-Sicot J, Pessayre D. [Iproniazid-induced hepatitis. The diagnostic value of a new antimitochondrial antibody anti-M6]. Gastroenterol Clin Biol 1983; 7: 529-32.
197. Neuberger J, Williams R. Immune mechanisms in tienilic acid associated hepatotoxicity. Gut 1989; 30: 515-9.
198. Lecoeur S, Bonierbale E, Challine D, et al. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem Res Toxicol 1994; 7: 434-42.
199. Vidali M, Hidestrand M, Eliasson E, et al. Use of molecular simulation for mapping conformational CYP2E1 epitopes. J Biol Chem 2004; 279: 50949-55.
200. De BV, Moulis C, Maurice M, et al. Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes. Mol Pharmacol 2000; 58: 542-51.
201. Maniratanachote R, Shibata A, Kaneko S, et al. Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. Toxicology 2005; 216: 15-23.
202. Eliasson E, Stal P, Oksanen A, Lytton S. Expression of autoantibodies to specific cytochromes P450 in a case of disulfiram hepatitis. J Hepatol 1998; 29: 819-25.
203. Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK. Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. Br J Clin Pharmacol 1992; 33: 183-186.